个体化给药方案舒尼替尼一线治疗转移性肾细胞癌的疗效与安全性:一项2期临床试验
本2期试验纳入117例转移性透明细胞肾细胞癌患者,起始舒尼替尼50 mg/日、计划用药28天、停药间隔缩短至7天,依据毒性个体化调整剂量与用药天数。中位无进展生存期为12.5个月(95%CI 9.6–16.5),中位总生存期为38.5个月(95%CI 28.3–未达到),客观缓解率46.1%、疾病稳定率38.5%,84.6%的患者获得临床获益。作者结论认为个体化舒尼替尼治疗可行、安全且能有效管理毒性。
要点
- 中位无进展生存期12.5个月,优于原假设的8.5个月(p<0.001)。
- 客观缓解率46.1%、疾病稳定率38.5%,84.6%的患者获得临床获益。
- 因毒性减量的患者占26.5%,因毒性停药者占7.7%,均低于标准给药。
核心结论
- 作者结论认为,个体化舒尼替尼治疗可行、安全,是管理毒性的有效方法,并取得口服血管内皮生长因子抑制剂治疗转移性肾细胞癌中较好的疗效之一。
研究设计与样本
- 这是一项2期临床试验,纳入117例转移性透明细胞肾细胞癌患者,起始舒尼替尼50 mg/日,目标治疗28天,治疗间歇缩短至7天。
- 舒尼替尼剂量与用药天数依据毒性个体化调整,目标为≤II级毒性,对毒性轻微者进行剂量上调。
- 主要终点无进展生存期的无效假设为8.5个月,依据是一项入组标准相似的研究。
- 临床试验注册号:NCT01499121。
主要发现
- 无效假设被拒绝(p<0.001),中位无进展生存期为12.5个月(95%CI 9.6–16.5)。
- 中位总生存期为38.5个月(95%CI 28.3–未达到)。
- 客观缓解率为46.1%,疾病稳定率为38.5%,84.6%的患者获得临床获益,治疗期间生活质量评分未见下降。
- 与标准舒尼替尼给药相比,因毒性减量的患者更少(26.5% vs 50%),因毒性停药的患者也更少(7.7% vs 18–20%)。
- 20例(18.4%)患者剂量上调至62.5 mg(12例)和75 mg(8例),最佳剂量与治疗持续时间存在较大个体差异。
关键数值与推荐
- 起始剂量为舒尼替尼50 mg/日,目标治疗28天,治疗间歇缩短至7天。
- 剂量上调至62.5 mg者12例,上调至75 mg者8例,合计20例(18.4%)。
- 因毒性减量者占26.5%,标准给药为50%;因毒性停药者占7.7%,标准给药为18–20%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sunitinib is administered on a rigid schedule that may not be optimal for all patients. We hypothesised that toxicity-driven dose and schedule changes would optimise drug exposure and outcome for each patient. MATERIALS AND METHODS: In a phase 2 trial, 117 patients with metastatic clear cell renal cell cancer were started on sunitinib 50 mg/day with the aim to treat for 28 days. Treatment breaks were reduced to 7 days. Sunitinib dose and the number of days on therapy were individualised based on toxicity aiming for ≤ grade II toxicity with dose escalation in patients with minimal toxicity. The null hypothesis for the primary end-point was a progression-free survival (PFS) of 8.5 months based on a study with similar eligibility criteria. RESULTS: The null hypothesis was rejected (p < 0.001) with a median PFS of 12.5 months (95% confidence interval [CI]: 9.6-16.5). The median overall survival was 38.5 months (95% CI: 28.3-not reached). The objective response rate (46.1%) and stable disease rate (38.5%) translated into a clinical benefit for 84.6% of patients with no decline in quality of life scores during therapy. Fewer patients were dose reduced (26.5% vs. 50%) or discontinued due to toxicity (7.7 vs. 18-20%) compared to standard sunitinib dosing, and 20 (18.4%) patients were dose escalated to 62.5 mg (12) and 75 mg (8) with a wide individual variation in the optimal dose and treatment duration. CONCLUSIONS: Individualised sunitinib therapy is feasible, safe and an effective method to manage toxicity with one of the best efficacy seen for oral vascular endothelial growth factor inhibitors in metastatic renal cell carcinoma. CLINICALTRIALS. GOV IDENTIFIER: NCT01499121.
引用
- Bjarnason GA, Knox JJ, Kollmannsberger CK, et al. The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial. Eur J Cancer. 2019. PMID: 30648632. doi:10.1016/j.ejca.2018.12.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。